Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MECA-TOX: Mechanisms of Action of Intrarectal Botulinum Toxin Injections in Fecal Incontinence
NCT05998187Phase 3Recruiting
- Sponsor
- Rouen University Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of neuronox in fecal incontinence (FI), sponsored by Rouen University Hospital. Primary endpoint: High amplitude propagative contractions at 1 month. Started Apr 2025; status: recruiting.
02
Drugs
neuronox
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT05998187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998187.